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Controla b s t r a c t
Schistosomiasis is one of the most important neglected tropical diseases (NTDs) affecting millions of peo-
ple in 79 different countries. The World Health Organization (WHO) has specified two control goals to be
achieved by 2020 and 2025 - morbidity control and elimination as a public health problem (EPHP). Mass
drug administration (MDA) is the main method for schistosomiasis control but it has sometimes proved
difficult to both secure adequate supplies of the most efficacious drug praziquantel to treat the millions
infected either annually or biannually, and to achieve high treatment coverage in targeted communities
in regions of endemic infection. The development of alternative control methods remains a priority.
In this paper, using stochastic individual-based models, we analyze whether the addition of a novel
vaccine alone or in combination with drug treatment, is a more effective control strategy, in terms of
achieving the WHO goals, as well as the time and costs to achieve these goals when compared to MDA
alone. The key objective of our analyses is to help facilitate decision making for moving a promising can-
didate vaccine through the phase I, II and III trials in humans to a final product for use in resource poor
settings.
We find that in low to moderate transmission settings, both vaccination and MDA are highly likely to
achieve the WHO goals within 15 years and are likely to be cost-effective. In high transmission settings,
MDA alone is unable to achieve the goals, whereas vaccination is able to achieve both goals in combina-
tion with MDA. In these settings Vaccination is cost-effective, even for short duration vaccines, so long as
vaccination costs up to US$7.60 per full course of vaccination. The public health value of the vaccine
depends on the duration of vaccine protection, the baseline prevalence prior to vaccination and the
WHO goal.
 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The World Health Organization (WHO) has noted that schisto-
somiasis is only second to malaria as the most devastating parasitic
disease in terms of socioeconomic importance and public healthimpact [1]. According to the latest Global Burden of Disease esti-
mates, more than 229 million people are infected with Schistosoma
species, including 124 million school-aged children - mostly in
sub-Saharan Africa [2]. Approximately 5–10% of individuals
infected by Schistosoma mansoni suffer from severe hepatic peri-
portal fibrosis which is the leading cause of death from schistoso-
miasis, and can lead to portal hypertension, hepatosplenomegaly
and esophageal varices [3].
Morbidity control and elimination as a public health problem
(EPHP) is defined by WHO as prevalence of heavy-intensity
4380 K. Kura et al. / Vaccine 38 (2020) 4379–4386infection in school-aged children (SAC, ages 5–14) 5% and 1%
respectively [4]. The WHO treatment guidelines are primarily
based on treating SAC only who typically harbor most infection
(a target MDA coverage of 75% is recommended), and those at high
risk of infection via mass drug administration (MDA) of the target
groups using praziquantel (PZQ) [2]. Despite the burden of disease
in pre-school-aged children (PSAC), the use of PZQ in this age
group is limited because a pediatric indication of PZQ is not avail-
able at present. A new formulation may make treating very young
children possible in the near future [5].
In this work we use the WHO-recommended treatment fre-
quencies, based on the pre-treatment baseline prevalence of infec-
tion in SAC [6]. We administer MDA once a year in high
transmission settings ( 50% baseline prevalence among SAC),
once every two years in moderate transmission settings (10–50%
baseline prevalence among SAC) and once every 3 years in low
transmission settings (<10% baseline prevalence among SAC).
Previous analyses based on mathematical models of transmis-
sion and MDA impact suggest that by following the WHO recom-
mended treatment coverage and frequency for MDA, the WHO
goals in low to moderate transmission settings can be achieved,
but it is highly unlikely that the goals will be achieved in high
transmission settings [7–14]. Furthermore, achieving high cover-
age levels of 75% in SAC required to reach the morbidity targets
will be difficult given past experience. The current MDA coverage
level reported byWHO for all endemic regions (international scale)
is 61.2% of SAC and 18.2% of adults [2,15].
Other issues with schistosome targeted MDA programs include:
(i) drug treatment does not prevent re-infection due to the absence
of protective acquired immunity and therefore repeated drug
administration is necessary; (ii) the emergence of drug resistance
is a constant threat as PZQ has been used for over three decades
[16,17]; (iii) a substantial infrastructure is required to ensure the
drug is supplied regularly within an acceptable time frame; (iv)
evidence is emerging of hybridization of human schistosome spe-
cies with those that typically infect livestock such that in some
regions the infection may become zoonotic with all the associated
problems of eliminating infection in humans in the presence of an
animal reservoir [18]; (v) limited supplies of the main drug PZQ in
settings wishing to implement community wide treatment; (vi)
high spatial heterogeneity in the prevalence of infection which
requires high resolution mapping of the prevalence of infection
to ensure the right communities are treated; and (vii) the necessity
to ensure that MDA coverage is high and that individual compli-
ance to treatment is good such that the proportion of persistent
non-compliers to treatment is very low to ensure they do not pro-
vide a persistent reservoir of infection [19].
Schistosomiasis is considered to be one of the 10 diseases where
vaccines are urgently required to be part of treatment programs to
reduce the probability of reinfection and eliminate the parasite in
endemic regions, particularly in high transmission settings [20].
At present there is no vaccine for use in humans that can protect
against schistosome infection. However, there are various candi-
date schistosomiasis vaccines in different stages of clinical trials
[21]. Monovalent recombinant protein Sm14 with GLA-SE adjuvant
has successfully completed phase I and phase II of clinical trials
with phase IIb underway in school-age children [21,22] Bilvax-
monovalent recombinant protein Sh28GST is another candidate
vaccine, against S. haematobium, that has successfully completed
phase I and phase II clinical trials. A phase III randomized con-
trolled trial was completed in Senegal (children only) to assess
the safety and efficacy of the vaccine. Published results show that
the vaccine induced a consistent immune response, but the efficacy
endpoint was not achieved [21,23,24]. We note here, that these
two vaccines target only one specific species.Sm-p80 is another promising candidate vaccine, considered as a
leading candidate as it can target three species, S. mansoni, S.
haematobium and S. japonicum [25]. Sm-p80 is a large subunit of
the S. mansoni calpain protein gene. This candidate vaccine has
been tested for the prophylactic and anti-fecundity efficacy in var-
ious vaccine formulations and delivery approaches, in three animal
models (mouse, hamster and baboon). It is shown that this vaccine
is effective against different stages of the parasite’s life cycle and
most importantly, Sm-p80 specific IgE has not been detected in
humans in endemic areas such as Africa and South America. This
implies that there might be a low probability of hypersensitivity
reaction following vaccination in humans [25,26].
Pre-clinical experimental studies, against Schistosoma mansoni
infection in a baboon model (Papio anubis) have produced very
encouraging results. The study showed greatly reduced female
worm establishment (by 93.45%) and tissue egg load (by 91.35%).
Another important factor is the duration of vaccine protection
and these experimental results suggest a 5–8 year duration of pro-
tection [27,28]. A phase I clinical trial, funded by the National Insti-
tutes of Health, is underway in the United States.
Evaluating the potential community-level impact of a schisto-
some vaccine to protect against the disease schistosomiasis is
required to quantitatively assess the benefits arising from what
will be a very large investment to get the candidate vaccine
through the development cycle. In such analyses, the cost per vac-
cine dose (or short course of doses) and the manner in which the
vaccine is going to be used, either as a stand-alone intervention
or in combination with other interventions such as mass drug
administration, are of utmost importance.
This paper presents results based on epidemiological and math-
ematical analyses of the potential impact of such a vaccine, used
either alone or in combination with MDA. The paper also details
a comparison of the cost-effectiveness of each intervention. The
aim is to provide policy insights that may help in decision making
during the various phases of clinical development about the cost
effectiveness of a vaccine with defined properties. Cost-
effectiveness analyses with clearly defined morbidity and mortal-
ity benefits over given time spans, taking account of different cost
estimates of each dose, or a short course of doses, are also essential
for impact assessment.
2. Methods
Individual-based stochastic models of parasite transmission
and control intervention impact have been developed indepen-
dently by Imperial College London (ICL) [11,14,29,30] and b) the
University of Warwick (UOW) [31]. Both models produce very sim-
ilar results for defined parameter sets (see Figure S.1-S.5). The
parameters used in this study are outlined in Table S6. In both
models we assume an ideal case perfect vaccine where the rate
of infection and the rate of egg production are reduced by 100%
(an assumption which is in good agreement with the baboon
Sm-p80 experiments described earlier), for a variety of population
or age-group coverage levels (where coverage is assumed to be at
random at each round of treatment-i.e. no systematic non-
adherence to MDA and/or vaccination) and vaccination uptake is
given at a defined age in all scenarios.
2.1. Description of control strategies
Experimental results have demonstrated that the Sm-p80 vac-
cine has a duration of protection between 5 and 8 years in animal
models [27]. There is no data on the duration of protection in
humans, so our analysis uses three different protection durations,
five years, ten years and an ideal case where the vaccine provides
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nation). The following six treatment strategies are examined.
1. Mass drug administration (MDA using PZQ) alone
This scenario addresses the question of whether the current
efforts are going to lead to morbidity control or EPHP, and over
what timescale. The following variations have been analyzed:
MDA given to SAC only with treatment coverage of (i) 75% (WHO
recommended), (ii) 60% or (iii) 40%. The treatment frequencies
are based on SAC baseline prevalences as defined by WHO.
2. Cohort Immunization
This scenario examines the questions of whether, and under
which conditions, a vaccine used alone achieves the goals of mor-
bidity control or EPHP. For routine vaccination, six scenarios were
simulated (shown in Table 1).
3. Cohort immunization with a catch-up vaccination campaign.
This scenario includes a round of immunizing SAC, with cover-
ages described in Table 1, before reverting to the same schedule as
cohort immunization after year 1. The purpose of the catch-up is to
have high coverage of the SAC age range from the beginning of the
intervention.
4. Immunization of whole age groups.
An alternative to immunizing children in cohorts is to target lar-
ger groups of the population with a lower frequency. The following
situations have been simulated: immunize annually, every two
years and every five years the SAC or the whole community with
coverage levels as described in Table 1
5. Cohort immunization + MDA.
This scenario examines the question of whether the addition of
a vaccine (stand-alone or in combination with PZQ) is a more effec-
tive approach - in terms of a desired impact and time to achieve
the impact - than MDA alone. The MDA and immunization pro-
gram are implemented concurrently, with duration of protection
and coverage levels from the scenarios described in use cases 1
to 4.
6. Cohort immunization with a catch-up campaign and MDA.
This scenario assesses the impact of the immunization of SAC in
year 0–1, before reverting to the same schedule as Cohort immu-
nization plus MDA after year 1.2.2. Epidemiological analysis
Each of these treatment strategies is evaluated for low, moder-
ate and high transmission settings (as defined by WHO andTable 1
Coverage levels (taken from within the ranges found in the literature for HPV and DTP [3
simulations.
20-year average duration of
vaccine protection
10-year average duration of vaccine protection
Vaccinate once at age 1 yr
(85% coverage)
Vaccinate twice at ages 1yrs and 11yrs (85% and
coverage, respectively)
Vaccinate once at age 5yrs
(60% coverage)
Vaccinate twice at ages 5yrs and 15yrs (60% and
coverage, respectively)detailed in the Introduction). At 15 years post initiation, we calcu-
late the probability of reaching the WHO morbidity and EPHP
(Elimination as a Public Health Problem) goals, by evaluating SAC
heavy-intensity infection prevalence (5% heavy-intensity infec-
tion in SAC for the morbidity goal and  1% heavy-intensity infec-
tion in SAC for the EPHP goal).
2.3. Cost-Effectiveness analysis
Cost-effectiveness calculations requires both a quantification of
the health benefits of a given treatment program as well as the
associated economic costs. To measure the benefit of applying an
intervention, we count the total number of days that each individ-
ual has a heavy intensity infection (HII) and record the total high
intensity infection years averted over a 30-year time period, rela-
tive to the baseline of no intervention. Heavy intensity infections
have been chosen as our measure because this is where most of
the negative health and societal effects occur.
The assumed costs of MDA, which are composed of the cost of
praziquantel and costs relating to the delivery and administration
of the drug to affected communities, are outlined in Table S5. The
costs related to MDA delivery were assumed to be dependent on
how many were targeted for the treatment and not the number
subsequently treated. The total cost related to the PZQ tablets
was directly dependent on how many were treated (Table S5). In
the absence of a manufactured product with known storage
requirements on shelf life expectancy, the costs of the vaccination
program are unknown. Analyses have therefore been performed
using three different costs of US$3, US$6 and US$12 per full course
of vaccination per person – i.e. we consider the cost of vaccination
as the cost the total number of doses needed to achieve immunity
and is not the per-dose price. This provides a more precise way of
comparing vaccines that may require different number of doses.
These three costs cover a range consistent with current GAVI Alli-
ance vaccine program costs, and are intended to include the cost of
the vaccine, the supply chain and of service delivery [36].
We quantify the cost-effectiveness of an intervention by the
high intensity of infection (HII) years averted per US$ spent over
the course of the intervention. As recommended by WHO a dis-
count rate of 3% per annum was applied to both the costs and
effects [37].
As well as considering specific vaccination costs, we calculate a
critical vaccination cost, which is the cost per person vaccinated,
relative to MDA per person treated, to achieve the same cost effi-
cacy as MDA. This can be considered to be a maximum price one
would be willing to pay for vaccination, on the assumption that
cost is the only deciding factor. In practice it may not be as simple
as this.
3. Results
3.1. Effectiveness of control strategies
In this section, for each treatment strategy, we evaluate the
probability of achieving the WHO goals 15 years post initiation2–35]) for the human host population for each treatment strategy examined in the
5-year average duration of vaccine protection [28]
70% Vaccinate three times at ages 1 yr, 6yrs and 11yrs (85%, 60% and 70%
coverage, respectively)
45% Vaccinate three times at ages 5yrs, 10yrs and 15yrs (60%, 70% and 45%
coverage, respectively)
4382 K. Kura et al. / Vaccine 38 (2020) 4379–4386of control. We find that the outcome depends on the transmission
intensity (the magnitude of the basic reproductive number, R0), the
goal and treatment strategy (vaccine only with different durations
of protection, MDA only, and vaccine plus MDA).
In low transmission settings, the WHO goals can be achieved for
all treatment strategies (Fig. 1, S.1-S.4 and Figure S.1). For MDA
alone, SAC coverage as low as 40% can achieve the morbidity con-
trol goal and potentially the EPHP goal (Fig. 1(a.)).
In moderate transmission settings, using the recommended tar-
get coverage of 75% for SAC, the SAC morbidity goal and EPHP goal
can be achieved within 15 years of the initiation of MDA (Fig. 1(a.)
and Figure S.2). When cohort immunization is considered alone,
the outcome depends on the duration of vaccine protection and
coverage levels achieved. A vaccine that provides 5 years of protec-
tion can achieve both goals within 15 years of the initiation of
treatment (Fig. 1(b.) and Figure S.3).
In high transmission settings MDA alone (with the recom-
mended 75% coverage) cannot achieve the WHO goals (Fig. 2(A)
and Fig. 1(a.)). Cohort vaccination can achieve the morbidity
control goal, but it is very unlikely to achieve the EPHP goal
(Fig. 2(B) and Fig. 1(b.)). We can modify this outcome by immuniz-
ing across bands of age classes (e.g. including adults). However,
this may risk a high frequency of adverse effects due to past or pre-
sent infection in vaccinated individuals. The best strategy in theseFig. 1. Projected outcomes for S. mansoni employing various control strategies as judged
1% elimination as a public health problem). Results for different durations of vaccine pr
moderate (10–50% baseline prevalence among SAC) and high (50% baseline prevalence
levels among SAC (assuming random compliance at each round of treatment). (b.) show
(c.) shows results for MDA plus immunization where the WHO target of 75% SAC coverag
ages vaccinated, while the second-row values (denoted by C:) represent the correspondcircumstances is intensive MDA targeted at SAC combined with
immunization. Treating 75% of SAC with MDA and vaccinating 1
and 11-year old can achieve the morbidity control goal with prob-
ability of 100% and the EPHP with a probability of nearly 90%
within 15 years (Fig. 2(C) and Fig. 1(c.)).
Alternatively, cohort immunization with a catch-up campaign
and MDA, or immunization of SAC/community every two years
can achieve the WHO goals within 15 years of treatment.
3.2. Cost-effectiveness using infant starting immunization programs
The simulation results presented in the previous section show
that the different treatment strategies can generate similar results
in terms of achieving the WHO goals. Logistical, programmatic and
cost issues will therefore play an important role in decision making
about which strategy to adopt and whether to proceed in vaccine
development.
Fig. 3 shows how the cost-effectiveness of each intervention
strategy compares in the high transmission setting, measured after
15 years of intervention, for a vaccine that confers 10 years of pro-
tection. We find that community-wide MDA is more cost-effective
than school-based MDA and is the most cost-effective strategy
when vaccination costs US$12. When vaccination costs less than
US$6, vaccination of SAC every 5 years is the most cost-effectiveby reference to achieving the WHO guidelines for control (5% morbidity control and
otection and vaccine coverage levels in low (<10% baseline prevalence among SAC),
among SAC) settings. (a.) represents results for MDA only with different coverage
s results for vaccine only with different durations of protection and coverage levels.
e is achieved. In (b) and (c) The first-row values (denoted by A:) represent the cohort
ing coverage levels. Results shown are generated by the ICL model.
Fig. 2. Prevalence of heavy-intensity infections in school-aged children (SAC) and adults for high transmission settings. Graph (A) represents MDA only scenario where MDA
is given to 75% of SAC. Graph (B) represents cohort immunization only scenario where the duration of vaccine protection is 10 years, vaccinating 1 and 11-year-old with
coverage of 85% and 70% respectively. Graph (C) represents SAC MDA + cohort immunization. Duration of vaccine protection is 10 years treating 1 and 11-year old with a
coverage of 85% and 70% respectively. MDA to 75% of SAC. Results shown are generated by the ICL model.
Fig. 3. Incremental cost-effectiveness ratio (ICER) diagrams, comparing costs to HII years averted across different interventions, in the high-transmission setting over
15 years, for a vaccine that confers 15 years of protection. Cohort vaccination starts at age 1. Left, middle and right plots compare interventions where vaccination costs $3, $6
and $12 per full course of vaccination, respectively. Radial gridlines indicate programs of equal cost-efficacy. In each ICER diagram, the marker with the bold outline indicates
the strategy that is most cost-effective. The dashed line shows the location of the efficient frontier, which estimates the maximum achievable HII years averted for a given
cost. Results shown are generated by the UOW model.
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cost-effective than school-based MDA when vaccination costs US
$6 or less. These patterns are repeated for vaccines with durations
of 5 and 20 years (Figure S.8).
For low and moderate transmission settings (Figure S.6 and Fig-
ure S.7), school-based MDA with 75% coverage is the most cost-
effective intervention when the cost of vaccination is US$6 or over,
for all vaccine protection durations. When vaccination costs US$3
and under, then vaccination of SAC every 5 years is the most
cost-effective intervention for all vaccine protection durations.
Other general trends we observe are: (i) In low and moderate
transmission settings, increasing coverage of children in SAC
MDA is more cost-effective than broadening the intervention to
include adults without increasing coverage in children, although
community-wide MDA is able to avert more high-intensity infec-
tions and reach the goal faster. (ii) A catch-up campaign becomes
increasingly beneficial for cohort vaccination as the duration ofvaccine protection increases. (iii) Community vaccination averts
the most heavy intensity infections, but they are the most costly
interventions. The longer the duration of vaccine protection, the
faster the intervention is able to break transmission, shown by
the decreasing trend in costs (purple triangles). (iv) With a vaccine
that confers 20 years of protection, cohort vaccination with a
catch-up campaign becomes close in terms of performance and
cost to the vaccination of SAC every 5 years. (v) Combining MDA
with vaccination increases the HII years averted but decreases
the cost-effectiveness of the strategy, because children are
treated/vaccinated multiple times, often unnecessarily. A more tar-
geted approach to chemotherapy with PZQ may offer higher cost-
effectiveness when used in conjunction with vaccination if the
costs of targeted delivery are not too high.
In Fig. 4, for high transmission settings we calculate a critical
vaccination cost for each intervention. This is the cost for a course
of vaccination that leads to the same cost-effectiveness figure as
Fig. 4. Critical vaccination costs for each intervention (relative to the most cost-
effective MDA scenario) in the high-transmission setting. Cohort vaccination starts
at age 1. Results shown are generated by the UOW model.
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should be paid for vaccination, should cost be the only deciding
factor.
Increasing the duration of protection lowers the critical vacci-
nation costs, except in cohort strategies that do not have a catch-
up campaign. This trend highlights the importance of a catch-up
campaign for vaccines with a long duration of protection when
employing a cohort program. The analyses suggest that even with
a vaccine which confers a relatively short duration of protection,
such as 5 years, it can be cost effective to pay up to US$7.60 per
vaccination (or short course of vaccination). The critical vaccina-
tion costs are lower in low and medium transmission settings
because re-infection after chemotherapy is slower, reducing the
benefits of vaccination relative to MDA.
3.3. Comparison of strategies using school-based immunization
programs
In Figures S.9-S.12 we compare the cost-effectiveness of immu-
nization strategies where immunization begins at age 5, in low,
moderate and high transmission settings. The results are qualita-
tively very similar to those above where we compared immuniza-
tion strategies that start at age 1 (Figures 3, S.6 and S.7). In contrast
to a cohort immunization strategy that starts with 1-year old
infants, there is no disadvantage employing a vaccine with a 20-
year duration of protection, in not having a catch-up campaign in
terms of cost effectiveness (Figure S8). However, as well as lower
costs, the heavy intensity infection years averted are greatly
reduced in the absence of the catch-up. Starting cohort strategies
at age 5 improves the cost-effectiveness as fewer immunizationsare required and children under 5 do not harbor significant para-
site burdens.4. Discussion
Our analyses suggest that the current program of intensive
Mass Drug Administration (MDA) using PZQ and targeted at
school-aged children (SAC) is unlikely to achieve the WHO goals
over a 15-year time-span, in high transmission settings. The
expected availability of a PZQ pediatric indication – expected
sometime in the first years of the next decade - will improve the
situation in terms of making it possible to treat the very young.
However, it will not address in any significant fashion the limita-
tions of MDA without achieving much higher coverage levels than
those that pertain in most endemic regions at present. It is also
important to bear in mind that the repeated use of PZQ at high cov-
erage levels may lead to the emergence and spread of drug-
resistant parasites, rapidly negating the efficacy of this drug. It is
therefore important that other forms of control, in particular
immunization, are actively explored.
Of the scenarios examined, high intensity programs, such as
community wide MDA or community wide immunization, have
the greatest impact on the burden of heavy intensity infection in
the community, and have the greatest chance of achieving the
WHO goals of morbidity control or EPHP. For strategies targeted
at school-aged children, immunization of age-cohorts combined
with MDA and a catch-up campaign have the highest probabilities
of meeting the WHO goals. However, in low to moderate-
transmission settings less intense strategies can also be successful.
Immunization is therefore likely to have a clear role to play in the
control of schistosomiasis, in high-transmission setting and if the
long-term goal is to break the transmission cycle, provided the cur-
rent candidate vaccine is successfully navigated through the devel-
opment cycle.
The most cost-effective strategy is highly dependent on the
transmission-setting, the duration of vaccine protection, the level
of coverage that can be obtained and the cost of the treatments.
It is also dependent on other factors such as whether the vaccine
can be safely administered to those who already have experience
of infection or who are currently infected. If the vaccination
induces adverse events in such individuals, then vaccination will
have to be restricted to infants in a cohort program with no
catchup activity. Another factor of importance is the time scale of
analysis and the assumption that the greatest proportion of PZQ
currently employed in MDA programs continues to be donated free
of charge such that the only cost is that of delivery and administra-
tion to individuals.
The following discussion assumes that (i) both adverse events
post immunization are not common, and (ii) the drug will continue
to be donated for the foreseeable future. In low and moderate
transmission settings MDA is the most cost-effective strategy over
the times scales considered, with high-coverage of school age chil-
dren being the best of all the strategies considered. In high-
transmission settings, and for vaccines that offer 5 years or more
protection, immunization of all school-aged children every 5 years
is the most cost-effective strategy simulated. It results in a larger
decline in heavy intensity infection than school-based MDA alone.
This strategy would remain the most cost-effective strategy in high
transmission settings for a vaccine that costs up to US$9.20 per full
vaccination (including delivery and vaccine costs). The analysis we
have performed assumes that vaccination programs begin without
any prior control, but in reality, the most likely scenario is that vac-
cination in area will commence after having received rounds of
MDA. For a given baseline transmission intensity, this will lower
the cost-effectiveness estimates. Further analysis, with good qual-
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settings, will improve our results.
It should be noted here that the total cost for full clinical devel-
opment of the candidate (through first into humans, and through
phase I to III trials) must not be a deterrent to the current major
vaccine manufacturing companies. There also needs to be the nec-
essary infrastructure to deliver the vaccine to the appropriate age-
groups at appropriate intervals given that the properties of the
candidate are not known at present, in terms of storage and
shelf-life. Also, with respect to catch up campaigns, an infrastruc-
ture in health delivery must be established to deliver immuniza-
tion across a wide band of age classes.
The efficacy of the vaccine in humans is obviously a very impor-
tant consideration. In this study we have modelled the effect of a
vaccine that offers perfect protection from infection, which is very
close to the effect of the Sm p80 vaccine in the baboon animal
model, where the multiple modes of action each have efficacies
greater than 90%, which when combined give a near perfect vac-
cine [27,28]. At this early stage of development, it is too soon to tell
if this level of efficacy will be matched in human hosts. However,
our simulated results suggest that even a partially efficacious vac-
cine that reduces fecundity by 75% and worm establishment by
75% produces similar results to the ideal vaccine, due to the multi-
plicative effect of the vaccine characteristics (see Fig S12). How-
ever, an inability to achieve an adequate efficacy, a good duration
of protection and affordable pricing points would necessitate a
re-evaluation of whether to proceed with vaccine development.
The choice of whether or not to proceed with clinical develop-
ment of a candidate vaccine is also dependent on a set of contex-
tual factors and conditions. For example,: (i) the desired goal
(morbidity control, EPHP, full interruption of transmission) will
dictate the need for a vaccine where transmission interruption is
unlikely to be achieved without immunization, (ii) the proportion
of remaining high transmission regions over all endemic settings
where a vaccine is most cost effective and (iii) the greater the risk
of PZQ resistance and hybridization of Schistosoma species, the
greater the need for a vaccine to prevent infection in humans.
If the desired goals combined with a broad risk assessment, call
for a vaccine to be part of the control strategy and that the required
vaccine characteristics can be achieved, much can be learnt from
the role out of the meningococcal bacterial vaccines in resource
poor settings. The approach adopted for the MenAfriVac vaccine
[38,39], was one where the prospective producer shares the risk
with a public health player (e.g. aid agency, UN agency, philan-
thropic organization) that provides some form of financial
incentive.
Any manufacturer of the vaccine will face risks in a number of
areas. These include (i) the ability of the development program
to confirm the high effectiveness in humans that has been demon-
strated in non-human primates, (ii) uncertainty in the availability
of a suitable adjuvant, (iii) the potential impact of PZQ and previ-
ous infection on vaccine efficacy and/or the occurrence of adverse
events, (iv) the absence of clearly defined correlates of protection
that could make the approval process longer and more expensive
and (v) the achievable cost of goods and hence the price of the vac-
cine whose level affects the overall viability of the initiative.
If the stages of first into humans and the phase I clinical trials in
humans go well, the early identification of a suitable manufacturer
(possibly from the emerging economies) who is prepared to take
the risks outlined above is crucial. Areas with endemic S mansoni
infection are primarily in Africa and clinical trials will need to be
run in this region. Partnering the potential manufacturer with rel-
evant bodies in Africa will be crucial to success as well illustrated
by the recent development and trials of a Plasmodium falciparum
vaccine (RTS, S) [40].5. Conclusions
Our analyses suggest that MDA alone can achieve the WHO
goals in low to moderate but not in high transmission settings.
The simulation studies clearly indicate that a vaccine is needed
to both reduce the probability of reinfection and eliminate trans-
mission within a reasonable time frame. The value of the vaccine
depends on, the duration of vaccine protection, the public health
goal (reduction in the prevalence of infection or the prevalence
of heavy-intensity infection) and the cost of the treatment. In high
transmission settings, vaccination alone may achieve the morbid-
ity control goal, but integrated MDA plus vaccination is required
to achieve the EPHP goal. In these settings, vaccination can be more
cost-effective than the current MDA programmes.CRediT authorship contribution statement
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